Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565118 | 0.93 | CXCR4 (0.50) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL28281040 | 0.89 | CXCR4 (0.44) | CXCR4SMN1; SMN2 | |
| SCHEMBL11019863 | 0.84 | CXCR4 (0.67) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL28322579 | 0.84 | CXCR4 (0.67) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL27866208 | 0.83 | ALDH1A1 (0.47) | CXCR4SMN1; SMN2 | |
| SCHEMBL14576195 | 0.81 | — | — | |
| SCHEMBL27866214 | 0.81 | ALDH1A1 (0.44) | CXCR4SMN1; SMN2 | |
| SCHEMBL1003923 | 0.80 | CXCR4 (0.75) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL8198989 | 0.80 | CXCR4 (0.75) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL472205 | 0.80 | CXCR4 (0.75) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | Ela Pharma Ltd (IL) | 2024-04-02 | — | — | US | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2021-10-07 | — | — | US | disclosed |
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | ELA PHARMA LTD. (IL) | 2021-04-06 | — | — | US | disclosed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | disclosed |
| CN-104718188-B | The benzamides of N- substitutions and its purposes in treating pain | 基因泰克公司 | 2018-08-21 | — | — | CN | disclosed |
| EP-3280401-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | disclosed |
| CN-104718188-A | N-substituted benzamides and their use in the treatment of pain | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| EP-0251194-B1 | USE OF CARBOCYCLIC AND HETEROCYCLIC CONDENSED DIHYDROPYRIDINES FOR THE PREPARATION OF CARDIOPROTECTIVE REMEDIES AND HETEROCYCLIC AND CARBOCYCLIC CONDENSED DIHYDROPYRIDINES AND METHODS AND INTERMEDIATES FOR THEIR PREPARATION | BOEHRINGER INGELHEIM KG (DE) | 1993-03-31 | — | — | EP | disclosed |
| EP-0251194-A1 | Use of carbocyclic and heterocyclic condensed dihydropyridines for the preparation of cardioprotective remedies and heterocyclic and carbocyclic condensed dihydropyridines and methods and intermediates for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSV, CTSA | CXCR4 795/4885SMN1; SMN2 3342/4885HIF1A 2283/4885 |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | CXCR4 893/4885SMN1; SMN2 3741/4885HIF1A 763/4885 |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSA, CPA1 | CXCR4 1181/4885SMN1; SMN2 3724/4885HIF1A 833/4885 |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CTSA, CTSG, CELA1 | CXCR4 794/4885SMN1; SMN2 3451/4885HIF1A 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.